Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
ZypAdhera ® (olanzapine pamoate monohydrate)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
ZypAdhera® (olanzapine pamoate): Administration of Olanzapine Pamoate
Olanzapine pamoate is for deep intramuscular gluteal injection only. Do not administer intravenously or subcutaneously. For full information on reconstitution and administration please refer to the summary of product characteristics.
Injection Based on Label Information
Confirm the final ZypAdhera suspension volume to injectconfirms the final ZypAdhera suspension volume to inject. Suspension concentration is 150 mg/ml olanzapine.1
Dose (mg) |
Final volume to inject (ml) |
150 |
1.0 |
210 |
1.4 |
300 |
2.0 |
405 |
2.7 |
Suspension concentration is 150 mg/ml olanzapine.
1. Determine which needle will be used to administer the injection to the patient. For obese patients, the 50 mm is recommended for injection:1
▪ If the 50 mm needle is to be used for injection, attach the 38 mm safety needle to the syringe to withdraw the required suspension volume.
▪ If the 38 mm needle is to be used for the injection, attach the 50 mm safety needle to withdraw the required suspension volume.
2. Slowly withdraw the desired amount. Some excess product will remain in the vial.1
3. Engage the needle safety device and remove needle from syringe.1
4. Attach the selected 50 mm or 38 mm safety needle to the syringe prior to injection. Once the suspension has been removed from the vial, it should be injected immediately.1
5. Select and prepare a site for injection in the gluteal area. DO NOT INJECT INTRAVENOUSLY OR SUBCUTANEOUSLY.1
6. After insertion of the needle, aspirate for several seconds to ensure no blood appears. If any blood is drawn into the syringe, discard the syringe and the dose and begin reconstitution and administration procedure again.
The injection should be performed with steady, continuous pressure.1
DO NOT MASSAGE THE INJECTION SITE.1
7. Engage the needle safety device (Instructions for Needle Safety Device- Fig. 1 and 2).1
8. Discard the vials, syringe, used needles, extra needle and any unused solvent in accordance with appropriate clinical procedures. The vial is for single use only.1
References
1ZypAdhera [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Date of Last Review: 23 December 2020